Skip to content
Search

Latest Stories

Chief pharmacist for England answers questions on professional leadership commission

Chief pharmacist for England and a co-chair on the professional leadership commission has responded to the questions raised by Pharmacists Defence Association (PDA) members on professional leadership.

In early September, the PDA wrote to the UK’s Chief Pharmaceutical Officers to increase transparency and confidence in the process by asking for clarification of some of the commission’s thinking, assumptions, and scope.


On behalf of all four CPhOs, chief pharmacist for England, David Webb, provided his feedback, saying: “The Commission has two independent co-chairs and members have agreed to abide by the seven principles for the conduct of public life as recommended by the Nolan Commission which forms part of the Terms of Reference.

"Commission members have been appointed on behalf of all pharmacy professionals to contribute their expertise in and knowledge of professional leadership and are not appointed to represent their particular countries, organisations, sectors or roles.

“The CPhOs act as advisors to the Commission and the final report will be authored by the co-chairs in consultation with Commission members. A Call for Evidence survey analysis and report writing is being conducted by an independent external organisation.

He said the survey was not intended to focus on any specific professional leadership body but that were were many such bodies that relate to pharmacy professionals across the UK.

“The work is being funded by the Offices of the four UK chief pharmaceutical officers.”

Later, the commission also shared a response on PDA’s members question on what was meant by “pharmacy professionals”? What prompted the formation of the commission and what expertise do individual members of the commission have?

Their response stated:

  • “The Commission was set up by the CPhOs with the broad aim to support and strengthen pharmacy professional leadership to enable excellence in patient care. There are significant changes occurring – and which will continue to evolve – which impact on the pharmacist and pharmacy technician professions and we need to ensure that they are well equipped with a voice to help shape the future, and enabled to develop through determining best practice, sharing and learning from it.  Strong, effective and well-respected professional leadership, which represents the clinical voice of pharmacy professionals, is required to guide, support and enable these transformational changes so they benefit patients and professionals. The final recommendations of the Report of the Commission are a matter for the Co-Chairs.”
  • “It is an independent Commission, co-chaired by independent non pharmacy professionals, with significant expertise and experience in professional regulation and leadership.”
  •  “The Commission members have been invited to participate based on their knowledge and expertise in professional leadership in its various guises.”
  • “All pharmacy professional leadership bodies are included – the RPS, APTUK and PSNI; to this should be added all those groupings who represent pharmacists in particular areas of practice, such as the British Oncology Pharmacy Association, and the UKCPA, for example.”
  •  “Pharmacy professionals are registered pharmacists and pharmacy technicians.”

However, the response came in too late to be shared, just a few hours before the midnight deadline for submissions.

Details of the full range of questions asked by PDA members and the rationale can be found here.

More For You

Pharmacist Support calls for birthday donations to meet rising demand for mental health services

More and more pharmacy professionals are reaching out for help, said Danielle Hunt.

Pharmacist Support's birthday appeal: Donate to address growing mental health demand

Pharmacist Support – the independent charity dedicated to the pharmacy profession – is celebrating 184 years of service with the launch of a special birthday donations appeal.

On 15 April, the charity is urging individuals and organisations across the sector to support its campaign to raise vital funds to meet the increasing demand for its mental health and wellbeing services.

Keep ReadingShow less
Prostate cancer: At-home saliva test could save NHS £500 million annually

PRS saliva test can identify prostate cancer that was missed by an MRI scan

Photo credit: gettyimages

Prostate cancer: Spit test better than blood test in spotting men at highest risk

A simple at-home spit test could help detect prostate cancer earlier, saving the NHS around £500 million a year, according to new research published in the New England Journal of Medicine.

Funded by the National Institute for Health and Care Research (NIHR), the study found that the DNA-based saliva test was more accurate than the current prostate-specific antigen (PSA) blood test in identifying men at risk of developing prostate cancer.

Keep ReadingShow less
RPS launches innovative new learning resources for members

With RPS Learn, pharmacists can develop a new skill or improve their understanding of practice or a clinical topic.

Gettyimages

RPS launches new learning resources to boost career development for members

The Royal Pharmaceutical Society (RPS) has launched a new online learning platform designed to support the practice, development and career advancement of its members.

The new platform, called RPS Learn, offers a diverse range of bite-size learning content, available on-demand, catering to all levels — from introductory to advanced and specialist —combining new content with RPS's renowned expertise in education and training to achieve excellence for learners.

Keep ReadingShow less
NICE approves AstraZeneca’s twice-a-day tablet ‘capivasertib’ for advanced breast cancer

HR-positive, HER2-negative advanced breast cancer is currently incurable, and treatment aims to slow progression and prolong life

Gettyimages

NICE approves twice-a-day tablet for advanced breast cancer

Every year, thousands of people with hormone receptor (HR)-positive HER2-negative breast cancer could benefit from a new twice-a-day tablet, now set to be funded immediately through the Cancer Drugs Fund.

The National Institute for Health and Care Excellence (NICE) has approved the use of capivasertib (also known as Truqap), in combination with fulvestrant, as an option for around 1,100 adults with HR-positive HER2-negative breast cancer that has certain genetic mutations and has spread.

Keep ReadingShow less
ABPI and government fast-track VPAG scheme review to address high medicine payment rates

The 2025 VPAG payment rate for newer medicines has been set at 22.9 per cent.

Photo credit: gettyimages

Review of 2024 VPAG scheme to be completed by June

The Association of the British Pharmaceutical Industry (ABPI) and the government have agreed to bring forward a planned review of the 2024 Voluntary Scheme for Branded Medicines Pricing, Access, and Growth (VPAG), originally scheduled for autumn 2025.

The review is expected to be completed in June 2025, aligning with the anticipated release of the government’s 10-year NHS Plan and the Life Sciences Sector Plan as part of the broader industry strategy this summer.

Keep ReadingShow less